1-3 of 3
Brittany D. Wolfe
Close
Sort by
Journal Articles

Prospective Trial Using Multimodal Measurable Residual Disease Negativity to Guide Discontinuation of Maintenance Therapy in Multiple Myeloma (MRD2STOP)

Ben A. Derman, Ajay Major, Sarah Major, Brittany D. Wolfe, Martha Gorski, Jennifer H. Cooperrider, Evangelia Andreatos, Ken Jiang, Karson Buckley, Amanda McIver, Andrew Stefka, Andrzej Jakubowiak
Journal: Blood
Blood (2022) 140 (Supplement 1): 2108–2109.
https://doi.org/10.1182/blood-2022-158643
Published: 2022
Journal Articles

Global Health Status Inadequately Captures Longitudinal Changes in Quality of Life in Patients Receiving Carfilzomib for Multiple Myeloma: Electronic Patient-Reported Outcomes (ePROs) from a Prospective Observational Study

Ajay Major, Nicole Prabhu, Claire Cunningham, Jennifer H. Cooperrider, Hannah Johnston, Evangelia Andreatos, Martha Gorski, Sarah Major, Brittany D. Wolfe, Eric Kruse, Ben A. Derman, Roberto M. Lang, Andrzej Jakubowiak, Jeanne DeCara
Journal: Blood
Blood (2022) 140 (Supplement 1): 12593–12595.
https://doi.org/10.1182/blood-2022-157795
Published: 2022
Journal Articles

Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)

Todd Zimmerman, MD, Noopur S. Raje, Ravi Vij, Donna Reece, MD, Jesus G. Berdeja, MD, Leonor A Stephens, PhD, Kathryn McDonnell, Cara A. Rosenbaum, MD, Jagoda Jasielec, MD, Paul G Richardson, MD, Sandeep Gurbuxani, Jennifer Nam, Erica Severson, Brittany D. Wolfe, MMS, PA-C, Shaun Rosebeck, PhD, Andrew Stefka, Dominik Dytfeld, MD PhD, Kent Griffith, PhD, Andrzej Jakubowiak, MDPhD
Journal: Blood
Blood (2016) 128 (22): 675.
https://doi.org/10.1182/blood.V128.22.675.675
Published: 2016